On April 8, 2025, the National Union of Health Insurance Funds issued an update to the Common Classification of Medical Procedures (CCAM), which serves as a reimbursement nomenclature for medical procedures in hospital and ambulatory settings. Changes include the introduction of new procedure codes, provisional registration of several procedure codes, and modification of existing services. Newly introduced procedure codes concern cardiovascular and peripheral vascular procedures, interventional radiology, ENT, and others. The update takes effect on July 1, 2025.

In March 2025, the entity managing the DRG system in Switzerland, SwissDRG, announced that they would be accepting applications for changes in the DRG system from June 2, 2025, until July 14, 2025. The results of the DRG applications made in 2025 will be reflected in the 2027 version of the SwissDRG.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Friedericy et al. assessed the environmental footprint of inhalation anaesthetics in Dutch hospitals and surveyed anaesthesiologists on practice patterns. A comprehensive 2019 bottom-up evaluation of anaesthetic agent procurement across the Netherlands was conducted. The analysis revealed relatively low greenhouse gas emissions, largely due to the widespread preference for intravenous anaesthesia and the limited use of inhalation-based techniques.

On April 4, 2025, NHS England published the final NHS Payment Scheme (NHSPS) for the 2025/26 financial year (starting on April 1st), defining payment mechanisms for the provision of NHS-funded hospital and ambulatory care and some public health services. No significant changes were made to the general payment model. The key changes include the introduction of reimbursement for activities from Community Diagnostic Centres and a new Best Practice Tariff to incentivize shifting suitable procedures from day case/hospital to outpatient settings.

On April 1, 2025, the revised EBM (German Uniform Evaluation Standard) catalog for the second quarter of 2025 came into force. The main changes introduced concern updates of the contents (services legends, preambles of several EBM subchapters) and the introduction of new EBM codes related to follow-up and evaluation of another reimbursable health app and second-opinion consultations.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Polmear et al. examined the growing application of Bayesian statistical methods in orthopedic research, highlighting their advantages over traditional P value-based approaches. The authors emphasized how Bayesian analysis can offer more nuanced interpretations in clinical contexts. Through practical examples ‒ such as diagnostic decision-making in prosthetic joint infection and comparative analysis from the orthopedic trial ‒ the review illustrated key Bayesian concepts and offered guidance for critically evaluating such studies.

MTRC is pleased to announce the release of its latest White Paper: "Reimbursement and HTA - Things You Might Be Missing". This document highlights the challenges market access professionals face in staying current with reimbursement and HTA developments and examines how the MTRC Market Access Monitor can help bridge these gaps.

MTRC is pleased to announce the release of its latest White Paper: "Case study: Market Access Pathway for TAVI in France". This document provides a detailed case study on how developers of medical technology (specifically - implants) can successfully navigate reimbursement pathways in key European markets, focusing on France.

In March 2025, the Draft Order amending the Common Package of Benefits of the National Health System and some other related legislative orders were released for public consultation. The Draft Order focuses on updating public health and primary care services, expanding neonatal and cancer screenings, improving equity in access to in-vitro fertilization, refining rehabilitation definitions, including patients in genetic advisory bodies, and modifying the system for ortho-prosthetic products.

MTRC is pleased to announce the release of its latest White Paper: "Reimbursement Pathways for Companion Diagnostic (CDx) Tests in Europe". This document provides a comprehensive overview of the reimbursement landscape for CDx tests in five largest European countries: England, France, Germany, Italy, and Spain.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Goetz et al. examined where EUnetHTA guidance documents require further methodological clarity in light of the upcoming EU HTA regulation. Through a systematic document review and structured stakeholder discussions conducted in Austria, the authors identified 32 key areas in need of refinement ‒ primarily related to evidence synthesis and eligibility criteria. Drawing on established HTA and evidence synthesis handbooks, the authors proposed concrete methodological options, offering actionable insights to support implementation across EU member states.

The French National Authority for Health (HAS) has released new recommendations regarding add-on reimbursement for medical devices and medical aids following the March 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Six favorable opinions were published concerning the registration of new devices or modifying conditions/indications for existing ones in the List of Reimbursable Products and Services (LPPR). The recommendations relate to devices in the fields of cardiovascular, peripheral vascular, endocrine, neuromodulation, and medical aids.